

Haematologica  
HAEMATOL/2019/219139  
Version 4

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Vittorio Montefusco, Francesca Gay, Stefano Spada, Lorenzo De Paoli, Francesco Di Raimondo, Rossella Ribolla, Caterina Musolino, Francesca Patriarca, Pellegrino Musto, Pietro Galieni, Stelvio Ballanti, Chiara Nozzoli, Nicola Cascavilla, Dina Ben-Yehuda, Arnon Nagler, Roman Hajek, Massimo Offidani, Anna Marina Liberati, Pieter Sonneveld, Michele Cavo, Paolo Corradini, and Mario Boccadoro

Disclosures: Disclosures Montefusco: Janssen: Other: Speakers Bureau, Advisory Board; Amgen: Other: Advisory Board; Celgene: Speakers Bureau, Advisory Board. Gay: Roche: Other: Advisory Board; Seattle Genetics: Other: Advisory Board; BMS: Honoraria; Janssen: Honoraria; Celgene: Honoraria, Other: Advisory Board; Amgen: Honoraria; Takeda: Honoraria, Other: Advisory Board. De Paoli: Gilead: Other: Advisory Board; Celgene: Other: Advisory Board; Amgen: Other: Advisory Board; Janssen: Other: Advisory Board. Di Raimondo: Celgene: Honoraria; Takeda: Honoraria, Research Funding. Patriarca: Celgene: Advisory Board & Travels; Janssen: Advisory Board & Travels; MSD Italy, Advisory Board & Travels; Jazz, Travels; Medac, Travels. Musto: Amgen: Honoraria; BMS: Honoraria; Takeda: Honoraria; Janssen: Honoraria; Celgene: Honoraria. Ballanti: BMS: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene: Honoraria. Nozzoli: Janssen: Advisory Board & Travels; Celgene: Advisory Board & Travels; Jazz, Travels; Bristol-Myers Squibb: Travels. Hajek: Takeda: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Novartis: Research Funding. Offidani: Amgen: Honoraria, Other: Advisory Board; Takeda: Honoraria, Other: Advisory Board; Janssen: Honoraria, Other: Advisory Board; Celgene: Honoraria, Other: Advisory Board; Bristol-Myers Squibb: Honoraria, Other: Advisory Board. Liberati: Bristol-Myers Squibb: Honoraria, Consultancy; Takeda: Advisory Board; Celgene: Honoraria; Abbvie: Honoraria and Advisory Board; Incyte: Honoraria, Janssen: Honoraria, Novartis: Honoraria, Amgen: Honoraria and Advisory Board. Cavo: GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or Advisory Board; Janssen: Honoraria, Membership on an entity's Board of Directors or Advisory Board, Research Funding, Speakers Bureau; Takeda: Honoraria, Membership on an entity's Board of Directors or Advisory Board; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or Advisory Board; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or Advisory Board; Amgen: Honoraria, Membership on an entity's Board of Directors or Advisory Board; Celgene: Honoraria, Membership on an entity's Board of Directors or Advisory Board, Research Funding, Speakers Bureau. Corradini: Gilead: Honoraria, Other: Advisory Board & Lecturer; Amgen: Honoraria, Other: Advisory Board & Lecturer; Takeda: Honoraria, Other: Advisory Board & Lecturer; Celgene: Honoraria, Other: Advisory Board & Lecturer; Roche: Honoraria, Other: Advisory Board & Lecturer; Sanofi: Honoraria, Other: Advisory Board & Lecturer; Sandoz: Other: Advisory Board; Novartis: Honoraria, Other: Advisory Board & Lecturer; Abbvie: Honoraria, Other: Advisory Board & Lecturer; Janssen: Honoraria, Other: Lecturer. Boccadoro: Janssen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; AbbVie: Honoraria; Bristol-Myers Squibb: Honoraria, Research Funding; Mundipharma: Research Funding; Amgen: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; Celgene: Honoraria, Research Funding.

Contributions: VM, FG and MB designed the study; FG and SS collected and assembled the data; SS and VM analyzed and interpreted the data; LDP, FDR, RR, CM, FP, PM, PG, SB, CN, NC, DBY, AN, RH, MO, AML, MC, PC provided patients; VM wrote the first draft of the manuscript; all authors had access to the final data and approved the final manuscript.